At Ksana Health, we provide our continuous behavior measurement platform (CBHM), Effortless Assessment of Risk States (EARS), to clinical researchers. This platform has given them richer insight into the passive behavior of their study participants. Recently, we have been exploring how this platform can help psychedelic pharma better understand the behavioral effects of its medications. An important incremental value of EARS is its ability to measure behavior in real-time, between clinic visits and beyond study participant self-reporting.
We are gratified to announce our first partnership with a psychedelic pharma company, Beckley PsyTech! This partnership focuses on the collection and analysis of digital biomarkers. This focus will identify signs of response and relapse in Phase 2 clinical trials. It will also track and improve the patient experience Beckley PsyTech is developing alongside its medication.
This partnership strengthens Ksana Health’s track record in applying its CBHM capability to a broad array of clinical research contexts. Read more in this press release.
If you are a researcher, running studies with real-world behavioral endpoints, we would love to demonstrate our capability for you. Our demo request form is here.
4 August 2022
Like any new health technology, continuous behavioral health measurement (CBHM) must economically justify its place among the growing options for measuring therapy and care outcomes. At Ksana Health, we think a lot...Continue reading
In September 2022, Ksana Health founders, Dr. Nick Allen and Will Short are quoted in an industry article highlighting the opportunistic role of remote patient monitoring (RPM) in behavioral health. Ideas...Continue reading
Ksana Health completed its first third-party assessment for security and privacy controls, receiving unqualified approval attesting to the strength of our controls and compliance with best practices and statutory requirements, including: AICPA,...Continue reading